Features  |   Technical Data  |   Ordering Info  |   Abstracts  |   Studies  |   Images  |   Download Brochure (pdf)

Sirolimus Eluting Stent

• Only stent incorporating variable strut thickness (VST) and variable strut design (VSD)
• Thin 60m S-Shaped articulations in mid portion ensures flexibility and avoids flare up of the struts
• Straight mid portion 90m articulations gives High Radial Strength
• Thicker metal coverage at the ends (120) to ensure more drug on the edges- Reduces edge restenosis.

Polymer

• Propriety blend of bio-compatible, bio-stable polymer
• Non-Inflammatory and Non-thrombogenic Polymer
• Polymer screened as per ISO 10993 Bio-compatibility tests
• Hemocompatibility test performed at NAMSA (North American Scientific Associates)

Drug

• Sirolimus most efficacious drug for stent delivery is used on stent
• Drug is cytostatic, acts on specific targets in the cellular proliferation cycle
• Sirolimus has the largest number of clinical trials and longest duration of follow-up as a drug on stent to reduce restenosis

Patented Vibrational Technology

• Patented Vibrational Technology ensures effective coating
• Drug loaded on the polymer matrix is securely attached to apre-functional stainless steel surface

Quality Control

• Stents and balloon catheters are manufacted in Germany
• Drug is exclusively licensed and procured from USA
• Drug is manufactured in a US FDA approved site under GMP conditions
• The final product is "finished" in an ISO 13485 facility

Release Kinetics

• About 50% of the drug is realeased within the first 10 days
• After 30 days, less than 25% of the drug remains on the stent surface
• Slow sustained realeased from the polymer matrix on the stent

Pronova comparative drug release kinetics